Differences
This shows you the differences between two versions of the page.
Both sides previous revision Previous revision Next revision | Previous revision | ||
content:mycophenolate_mofetil [2022/04/29 22:40] – administrator@icnapedia.org | content:mycophenolate_mofetil [2022/04/30 11:54] (current) – changed pubmed syntax administrator@icnapedia.org | ||
---|---|---|---|
Line 1: | Line 1: | ||
====== Mycophenolate Mofetil ====== | ====== Mycophenolate Mofetil ====== | ||
- | Mycophenolate Mofetil is indicated in combination with ciclosporin and corticosteroids for the prophylaxis of acute transplant rejection in patients receiving allogeneic renal, cardiac or hepatic transplants. | + | Mycophenolate Mofetil is indicated in combination with ciclosporin and corticosteroids for the prophylaxis of acute transplant rejection in patients receiving allogeneic renal, cardiac or hepatic transplants. MMF is promising in immune-mediated neuromuscular disorders. MMF has been used for the treatment of polymyositis, |
**Mechanism of action** | **Mechanism of action** | ||
Mycophenolate Mofetil is the 2-morpholinoethyl ester of MPA. MPA is a potent, selective, uncompetitive and reversible inhibitor of inosine monophosphate dehydrogenase, | Mycophenolate Mofetil is the 2-morpholinoethyl ester of MPA. MPA is a potent, selective, uncompetitive and reversible inhibitor of inosine monophosphate dehydrogenase, | ||
+ | |||
+ | ===== References ===== | ||
+ | ~~REFNOTES~~ |